Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, Cai Y, Wallin JJ, Zhang L, Humeniuk R, Begley R, Geleziunas R, Mellors J, Wrin T, Jones N, Milush J, Ferre AL, Shacklett BL, Laird GM, Moldt B, Vendrame E, Brainard DM, Ramgopal M, Deeks SG. SenGupta D, et al. Among authors: vendrame e. Sci Transl Med. 2021 Jun 23;13(599):eabg3071. doi: 10.1126/scitranslmed.abg3071. Sci Transl Med. 2021. PMID: 34162752 Clinical Trial.
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Cai Y, Podlaha O, Deeks SG, Brinson C, Ramgopal MN, DeJesus E, Mills A, Shalit P, Abdel-Mohsen M, Zhang L, de Vries CR, Vendrame E, SenGupta D, Wallin JJ. Cai Y, et al. Among authors: vendrame e. Eur J Immunol. 2024 Aug;54(8):e2350809. doi: 10.1002/eji.202350809. Epub 2024 May 10. Eur J Immunol. 2024. PMID: 38727191
Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.
Abdel-Mohsen M, Deeks S, Giron L, Hong KY, Goldman A, Zhang L, Huang SSY, Verrill D, Guo S, Selzer L, de Vries CR, Vendrame E, SenGupta D, Wallin JJ, Cai Y. Abdel-Mohsen M, et al. Among authors: vendrame e. Front Immunol. 2024 Jun 24;15:1405348. doi: 10.3389/fimmu.2024.1405348. eCollection 2024. Front Immunol. 2024. PMID: 38979421 Free PMC article. Clinical Trial.
Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.
Ivison GT, Vendrame E, Martínez-Colón GJ, Ranganath T, Vergara R, Zhao NQ, Martin MP, Bendall SC, Carrington M, Cyktor JC, McMahon DK, Eron J, Jones RB, Mellors JW, Bosch RJ, Gandhi RT, Holmes S, Blish CA; ACTG 5321 Team. Ivison GT, et al. Among authors: vendrame e. Front Cell Infect Microbiol. 2022 Feb 10;12:757846. doi: 10.3389/fcimb.2022.757846. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35223535 Free PMC article.
Human natural killer cells mediate adaptive immunity to viral antigens.
Nikzad R, Angelo LS, Aviles-Padilla K, Le DT, Singh VK, Bimler L, Vukmanovic-Stejic M, Vendrame E, Ranganath T, Simpson L, Haigwood NL, Blish CA, Akbar AN, Paust S. Nikzad R, et al. Among authors: vendrame e. Sci Immunol. 2019 May 10;4(35):eaat8116. doi: 10.1126/sciimmunol.aat8116. Sci Immunol. 2019. PMID: 31076527 Free PMC article.
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.
Riddler SA, Benson CA, Brinson C, Deeks SG, DeJesus E, Mills A, Para MF, Ramgopal MN, Cai Y, Zheng Y, Zhang L, Jiang W, Liu X, Verrill D, Lim D, de Vries CR, Wallin JJ, Vendrame E, SenGupta D. Riddler SA, et al. Among authors: vendrame e. Infect Dis Ther. 2024 Nov;13(11):2285-2299. doi: 10.1007/s40121-024-01034-w. Epub 2024 Sep 15. Infect Dis Ther. 2024. PMID: 39278975 Free PMC article.
32 results